HDI Audit

Key-person risk in cell & gene therapy

Updated 2 October 2026

In autologous therapy every batch is made for one patient, and the schedule starts with the patient, not the plant. That makes dependency on people more expensive here than in almost any other part of pharma: a decision that waits for one person can delay a patient's treatment.

Where does dependency concentrate in CGT?

Which KPIs does the screening use for CGT?

If you do not have a figure, the screening uses the industry median.

What does the audit look at in a CGT operation?

The workshop follows a patient's material from collection to infusion and asks, at each hand-off, who has to be present and what happens when they are not. Typical findings concern investigation know-how held by one person, scheduling that lives in one inbox, and identity records that lag behind the physical transfer. The sample report shows a fictional CGT company.

Start the free screening →